Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.40 |
| ▸ | HTR2B | P41595 | 5/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25004716 | 0.80 | SLC6A4 (0.39) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL25004337 | 0.78 | TLR7 (0.33) | SCN9ABACE1 | |
| SCHEMBL25005274 | 0.74 | HTR2C (0.34) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL15780114 | 0.73 | SLC6A4 (0.49) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL25005441 | 0.73 | SLC6A4 (0.49) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23995366 | 0.73 | SLC6A4 (0.38) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL21849069 | 0.70 | CYP1A2 (0.44) | BACE1 | |
| SCHEMBL23995528 | 0.70 | HTR2C (0.47) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23993580 | 0.70 | HTR2C (0.67) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL15767785 | 0.70 | HTR2C (0.67) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | HTR2C 1699/4885HTR2B 2352/4885SLC6A4 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.